

Press Release – For immediate release

BIOLIDICS TO BROADEN ITS PRESENCE IN CHINA’S CANCER DIAGNOSTICS MARKET WITH NEW PARTNERSHIP

- **4th partnership in the PRC with Zhongshan TopGene to develop and commercialise laboratory-developed tests (“LDTs”) in the field of circulating tumor cells (“CTCs”) using Biolidics’ ClearCell® FX1 System and CTChip® FR1 biochip**
- **Zhongshan TopGene is a wholly-owned subsidiary of TopGene, which specialises in precise diagnosis and treatment of cancer in the PRC**
- **Growing network of partnerships in the PRC provides Biolidics with more opportunities for value creation and strengthens its positioning as an upstream technology within the cancer diagnostic value-chain in the field of liquid biopsy**

Singapore, 25 June 2019 – Biolidics Limited (“Biolidics” or the “Company”), a medical technology company with a focus on cancer diagnostic solutions, is pleased to announce that it has entered into a new partnership with Zhongshan TopGene Medical Laboratory Co. Ltd. (“Zhongshan TopGene”) (“中山拓普医学检验实验有限公司”) to develop and commercialise LDTs in the field of CTCs using Biolidics’ ClearCell® FX1 System and CTChip® FR1 biochip.

Certified and licensed to undertake clinical trials in the People’s Republic of China (“PRC”), Zhongshan TopGene is a wholly-owned subsidiary of TopGene Tech (Guangzhou) Co., Ltd. (“TopGene”) (“广州拓普医疗科技有限公司”) which specialises in precise diagnosis and treatment of cancer in China.

Including this latest partnership, Biolidics has a total of 4 partnerships, with established medical and clinical laboratories, and medical technology companies specialising in precision medicine within the oncology field, for the development and commercialisation of such LDTs in the PRC.

These LDTs involve liquid biopsy, which is a cheaper, faster and simpler alternative to an invasive tissue biopsy, that enables doctors and patients to discover a range of information about a tumour through a simple blood sample.

The analysis of CTCs, employing Biolidics’ ClearCell® FX1 System, has been noted to be the most highly developed liquid biopsy technique, as the presence of CTCs is a fundamental prerequisite to metastasis and their enumeration offers great potential for both diagnosis and prognosis.

Mr. Ivan Lew (廖光品), Executive Director and CEO of Biolidics, said: *“We are at the beginning of what we believe will be the disruption and transformation in the field of cancer diagnostics by new and exciting developments in the area of liquid biopsy.”*

One of our key goals is to advance our novel patented technology within the oncology community in China and with our LDTs business model, we have a strong potential to develop innovative cancer diagnostic solutions that more cost-effective and accessible to cancer patients across China.”

- END -

About Biolidics Limited

(Bloomberg Code: BLD:Singapore / Reuters Code: BIOL.SI / SGX Code: 8YY)

Incorporated in 2009, Biolidics is a Singapore-based medical technology company focusing on the development of cell enrichment systems which, when combined with other analytical tests, have a wide range of applications for cancer diagnosis, prognosis, treatment selection and treatment monitoring.

Biolidics has developed and commercialised the ClearCell® FX1 System, a fully automated CE-IVD medical device which relies on a novel patented technology to separate and enrich cancer cells from blood.

The ClearCell® FX1 System, installed across Asia, Europe and North America, allows users of the system to perform liquid biopsies to test for the presence of cancer cells (specifically circulating tumour cells, or CTCs) in blood samples or perform further analysis on cancer cells.

Liquid biopsies (i.e. analysis of the circulating tumour cells in blood samples) have many applications throughout the various stages of a patient's cancer journey, from cancer screening and staging to personalised treatment, and post- cancer monitoring.

Biolidics' quality assurance capabilities have been recognised through its ISO 13485 certification, CE-IVD, US FDA Class I registration and NMPA (formerly CFDA) Class I registration (for the MGI EasyCell System).

For additional information, please visit www.biolidics.com.

Issued on behalf of Biolidics Limited by 8PR Asia Pte Ltd.

Media & Investor Contacts:



Mr. Alex TAN
Mobile: +65 9451 5252
Email: alex.tan@8prasia.com

This press release has been prepared by Biolidics Limited (the "Company") and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.